Press Releases

Press Releases

Date Title
Sep 14, 2021
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World
Sep 09, 2021
GBT Announces New Employment Inducement Grants
Sep 08, 2021
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Sep 07, 2021
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
Sep 02, 2021
GBT Announces Participation in Upcoming Investor Conferences
Aug 12, 2021
GBT Announces New Employment Inducement Grants
Aug 04, 2021
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
Aug 03, 2021
GBT Reports Second Quarter 2021 Financial Results
Jul 27, 2021
GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
Jul 22, 2021
GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD)
Jul 09, 2021
GBT Announces New Employment Inducement Grants
Jun 15, 2021
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
Jun 14, 2021
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
Jun 11, 2021
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Jun 04, 2021
GBT Announces New Employment Inducement Grants
Jun 01, 2021
GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference
May 12, 2021
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
May 07, 2021
GBT Announces New Employment Inducement Grants
May 06, 2021
GBT Announces Participation in Upcoming Investor Conferences
May 05, 2021
GBT Reports First Quarter 2021 Financial Results
May 04, 2021
GBT and Sickle Cell Disease Association of America Kick Off “Lift Every Voice to Shine the Light on Sickle Cell” Spoken Word Contest in Honor of World Sickle Cell Day 2021
Apr 28, 2021
GBT to Announce First Quarter 2021 Financial Results on Wednesday, May 5, 2021
Apr 08, 2021
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
Apr 05, 2021
GBT Announces New Employment Inducement Grants
Mar 18, 2021
GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors
Mar 16, 2021
GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
Mar 08, 2021
GBT Announces New Employment Inducement Grants
Mar 02, 2021
GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community
Mar 02, 2021
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
Feb 24, 2021
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
Feb 19, 2021
GBT Announces Participation in Upcoming Investor Conferences
Feb 17, 2021
GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
Feb 05, 2021
GBT Announces New Employment Inducement Grants
Feb 04, 2021
GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States
Jan 27, 2021
European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease